SIGi001-A-9 Bi-Allelic MAPT HA-tag
SIGi001-A-16
General#
Cell Line |
|
| hPSCreg Name | SIGi001-A-16 |
| Alternative name(s) |
SIGi001-A-9 Bi-Allelic MAPT HA-tag
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 20th April 2021 |
| Notes | SIGi001-A-9 (iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1) having a HA-tag at the C-terminal end of MAPT, Bi-Allelic |
| User feedback | |
Provider |
|
| Generator |
Bioneer (BION)
Contact:
Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA6080815 |
| CLO | CLO_0103295 |
| Cellosaurus | CVCL_A7GT |
| Wikidata | Q107116926 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research: allowed
Clinical: not allowed
Commercial: not allowed
|
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4447434 |
Ethics#
Also have a look at the ethics information for the parental line
SIGi001-A
.
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Bioneer |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation#
General |
|
|
The source cell information can be found in the parental cell line
SIGi001-A.
|
|
| Passage number reprogrammed | +15 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Unknown |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| SSEA-1 |
No |
Morphology pictures
Differentiation Potency
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
Passage number: +15
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification#
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.